NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Omeros Corporation (OMER) Stock Analysis

Omeros Corporation (OMER) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

OMER

$18.95

−$0.16 (−0.84%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OMER with… →

OMER Key Statistics

As of Sep 4, 2026
Trading
Open
$19.00
Previous Close
$19.11
Day's Range
18.90–19.23
52-Week Range
3.94–19.65
Volume
892.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.60
Valuation
Market Cap
$1.37B
P/E Ratio
11.48
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.55
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.81
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
35.70
EPS (ttm)Profit attributable to each share over the last twelve months.
1.65
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$3.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
324.88%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.39M
1-Year Return
+353.35%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
2.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OMER Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+10.30%
2025+73.89%
2024+202.14%
2023+44.69%
2022−64.85%
2021−55.00%
2020+1.42%
2019+26.48%
2018−42.67%
2017+95.87%
2016 (partial year)−20.64%

As of September 4, 2026.

OMER Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$3.35M—
2024$0.00−$156.82M—
2023$0.00−$117.81M—
2022$0.00$47.42M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$122.80M−$3.35M—
2024$0.00—−$166.95M−$156.82M—
2023$0.00—−$164.53M−$117.81M—
2022$0.00—−$163.39M$47.42M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OMER Valuation vs Biotechnology Median

Median of 656 stocks
MetricOMERBiotechnology medianvs median
P/E11.4812.579% below
P/S ratio35.7015.26134% above
Profit margin324.88%0.00%324.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Omeros Corporation (OMER) at $1.37B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 175 employees.

The 52-week range on file runs from $3.94 to $19.65. OMER last closed at $18.95 on September 4, 2026. That is −$0.16 (−0.84%) against the previous close. The latest close sits 380.96% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $3.35M. Profit margin runs at 324.88%. That is 324.9 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 1.65.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 11.48. That is 8.67% below the Biotechnology median of 12.57. The forward P/E on file is 16.55. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.81. Measured against sales, the shares trade at 35.7 times revenue. On price-to-sales that is 133.91% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 2.6. Annualized volatility over the trailing 10 years is 111.59%. The trailing one-year price return is +353.35%. Across 10 years the annualized return works out at +5.49%.

Growth & Income

The record shows no dividend for OMER.

So far in 2026 the price is +10.30%. Across the complete calendar years on file, 2024 returned +202.14% and 2022 returned −64.85%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Omeros Corporation (OMER) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Omeros Corporation OMER $1.37B 11.5
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Omeros Corporation trades at a P/E of 11.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Visit website →